Article

U.S. predicted to adopt premium IOLs more quickly than Europe, Japan

Waltham, MA-The U.S. ophthalmic market will embrace the use of premium IOLs rapidly, whereas less flexible reimbursement programs in Europe and Japan will delay the adoption of them in those markets, the Millennium Research Group (MRG) has forecast.

Waltham, MA-The U.S. ophthalmic market will embrace the use of premium IOLs rapidly, whereas less flexible reimbursement programs in Europe and Japan will delay the adoption of them in those markets, the Millennium Research Group (MRG) has forecast.

In many European countries, cataract procedures are reimbursed at a fixed amount and, therefore, premium IOLs are used only in procedures paid for with out-of-pocket funds, according to MRG. By comparison, in the United States, IOLs that have been granted new technology IOL reimbursement status receive additional Medicare reimbursement of $50 per lens for procedures performed in ambulatory surgical centers.
 
In Japan, said Cheyne Singh, an analyst at MRG, “advanced IOL technology has had slow adoption . . . mainly because of low reimbursement rates and a slow approval process. Many industry insiders consider the Japanese medical device regulatory approval process to be costly, time-consuming, and a major hindrance in developing the Japanese IOL market.”

Other predictions made by MRG, based on its research:

• The U.S. IOL market will surpass $980 million in sales in 2011, compared with $458 million in Europe and Japan combined.

• The U.S. market for IOLs is expected to grow significantly over the next 5 years, based on the growth of advanced IOL technology. Sales of lenses to address presbyopia and those with aspheric optic profiles will grow significantly due to heavy marketing campaigns by their manufacturers, the introduction of new lenses, and increased training of surgeons to implant such IOLs.

• The future growth of the European market for premium IOLs is highly contingent on a price reduction by manufacturers or increased reimbursement. As a result, the market for less costly traditional monofocal lenses (those made of hydrophobic, hydrophilic, silicone, or polymethylmethacrylate material) will remain strong in Europe over the next 5 years.

• The use of hydrophobic IOLs in Japan will increase over the next 5 years. In 2007, the majority of cataract procedures in Japan were performed using lenses made of that material.

• The Japanese IOL market also will gain considerable value from the increasing use of premium-priced, preloaded IOL injector systems.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.